Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp. is a biotechnology company that develops engineered cytokine therapies for the treatment of cancer. The company focuses on designing selective interleukin-based molecules, including interleukin-2, interleukin-4, and interleukin-13 variants, either independently or combined with cell-killing proteins and antibodies. Its primary product candidates include MDNA11 for advanced solid tumors, bizaxofusp for recurrent glioblastoma, and bi-functional therapies termed BiSKITs. These investigational treatments are designed for cancer patients with advanced solid tumors and high-grade brain cancers.

The company is headquartered in Toronto, Ontario, Canada, where it maintains its registered office. It operates through short-term office leases in Toronto and Houston, Texas, and maintains an international subsidiary in Australia. Medicenna conducts clinical trials across sites in Canada, the United States, and Australia. The organization does not own or lease any laboratory or manufacturing facilities, office furniture, or capitalized equipment.

Summary of the business section of Medicenna Therapeutics's latest annual report, written by StockData.

“As at March 31, 2023, Medicenna had 16 full-time employees and one part-time consultant, including seven holding PhD degrees, two with an MBBS and two employees holding CPA designations.”